Endosomal pH drives stemness in glioblastoma A group of researchers has shown that endosomal pH drives stemness in glioblastoma. The group discovered that endosomal Na+/H+ exchanger isoform 9 is a novel driver of stem cell-like characteristics -- or stemness -- in glioblastoma by stabilizing multiple receptor tyrosine kinases, according to a recent paper published in PNAS Nexus.Read More
Scientists improve ADC development with mix of experimental, computational tools BOSTON -- Greg Thurber, PhD, professor at the University of Michigan explained how his lab is jointly using both experimental animal models and computational models to improve the overall speed and efficiency of drug development of antibody-drug conjugates (ADCs) to get more of the agents on the market. Thurber presented in a scientific session at the Society for Laboratory Automation and Screening (SLAS) 2022 International Conference and Expo.Read More
Step toward broader treatment for Duchenne muscular dystrophy Current therapies to treat Duchenne muscular dystrophy, a genetic muscle-wasting disease, only work in a small proportion of people with the condition. Research published on February 21 in the Proceedings of the National Academy of Science provides a proof of concept for developing a therapy that could work for almost half of the people affected.Read More
How one company is helping make complex medicines safer Often, the most dangerous things in life are things that the human eye cannot see. This is true even for life-saving medicines. One company was founded to help the industry find these hidden particles and solve a key challenge in the development of complex drug products. Halo Labs’ CEO Rick Gordon spoke with ScienceBoard about how its low volume approach is providing a critical service for the drug development industry.Read More
Applied DNA and EvviVax publish data for potential cancer immunotherapy Applied DNA Sciences and EvviVax have published a manuscript detailing a preclinical study showing that LinearDNA vaccines used for cancer immunotherapy produced a strong immune and specific antitumoral response in preclinical mouse models. The study investigated the use of the LinearDNA platform to produce DNA vaccines targeting either tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs, or tumor neoantigens).Read More
Bio-Rad develops antidaratumumab antibodies for drug monitoring Bio-Rad Laboratories has launched a range of antidaratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars, according to the company.Read More
IsoPlexis uses proteomics to identify early factors of long COVID IsoPlexis has published a study in Cell, led by the Institute for Systems Biology and the Seattle COVID Consortium, in which researchers used IsoPlexis' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as post-acute sequelae of COVID-19 (PASC) or long COVID.Read More